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The interaction of bacterial pathogens with platelets 
 
J. Ross Fitzgerald, Dermot Cox and Timothy J. Foster 
 
Centre for Infectious Diseases, The Chancellor's Building, New Royal Infirmary, 
University of Edinburgh, Edinburgh EH16 4SB, Scotland, UK, Department of 
Microbiology, Moyne Institute of Preventive Medicine, University of Dublin, Trinity 
College, and Molecular and Cellular Therapeutics, School of Pharmacy, Royal College of 
Surgeons in Ireland, Dublin 2, Ireland. 
 
Preface 
In recent years, the frequency of serious cardiovascular infections such as endocarditis 
has increased, particularly in association with nosocomially-acquired antibiotic-resistant 
pathogens. Growing evidence suggests a critical role for the interaction of bacteria with 
human platelets in the pathogenesis of cardiovascular infections.  This paper reviews the 
nature of the interactions between platelets and bacteria and the role this plays in the 
pathogenesis of endocarditis and other cardiovascular infections. 
 
 
Introduction 
Opportunistic pathogenic bacteria can occasionally gain entry to the human 
circulatory system resulting in a transient bacteraemia. Serious complications of 
bacteraemia include life-threatening infective endocarditis (IE)1, disseminated 
intravascular coagulation (DIC)2, immune thrombocytopenia purpura (ITP)3 and even 
increased risk of myocardial infarction (MI)4, 5 or stroke6. All of these conditions are 
characterised by abnormal platelet function (see below) possibly mediated by a direct or 
indirect interaction with the invading pathogen. 
Bacteria-platelet interactions are characterised by binding of bacteria to platelets 
either directly via a surface protein on the bacteria7 or indirectly via a plasma bridging 
molecule linking bacterial and platelet surface receptors8. Platelet activation is a 
necessary step in thrombus formation and bacteria can induce activation either by a direct 
interaction with the platelet7 or indirectly through bridging molecules8 or secreted 
bacterial products9. Adhesion and activation can be independent processes mediated by 
different bacterial components and different platelet receptors. As a result bacteria can 
have an activating phenotype, an adhesive phenotype, both or neither. Different 
phenotypes may be specific to different diseases. Thus, bacteria with an adhesive 
phenotype may be critical for colonisation of a cardiac valve in IE while those with an 
activating phenotype may be necessary for the enhanced platelet consumption in DIC and 
thrombocytopenia. 
The interaction of bacteria with platelets may result in platelet activation. When 
this occurs in a localized manner the result is the formation of a thrombus (Figure 1).  It 
is our contention that endocarditis can occur on undamaged valves by small circulating 
thrombi caused by bacteria in the bloodstream. Also, sterile thrombi that form on 
damaged heart valves can become infected by circulating bacteria. In both cases 
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development of the infected thrombus involving bacterial activation of platelets on the 
surface of a heart valve can result in heart failure or a septic embolism.  If the interaction 
occurs in a more diffuse manner this can result in consumption of the activated platelets 
leading to thrombocytopenia or if there is an associated activation of coagulation it can 
result in disseminated intravascular coagulation.  
Platelet activation in the laboratory is commonly studied using light transmission 
aggregometry10. This technique is limited in its sensitivity and to obtain a maximal 
response bacterial cells are used at a concentration much higher than occurs in 
bacteraemia. There is no getting away from the fact that aggregation studied in an 
aggregometer is an artificial situation. However, the process of platelet activation in vivo 
can occur at very low densities of bacteria and can lead to severe thrombocytopenia due 
to amplification of the activation process.  This can be seen for example with H. pylori-
mediated thrombocytopenia where there is no evidence of  bacteraemia3. Platelet 
activation causes the release of thromboxane A2, ADP and serotonin all of which are very 
potent platelet activators. These lead to localized platelet activation and thrombus 
formation and if they are released to a sufficient extent cause massive consumption of 
platelets (thrombocytopenia).  This is characteristic of some bacterial infections such as 
those caused Helicobacter pylori11, 12 and haemolytic uremic syndrome caused by 
Escherichia coli13. Thrombocytopenia associated with bacterial infections is thought to 
occur secondarily to disseminated intravascular coagulation (DIC), a generalised 
activation of the coagulation cascade during bacteraemia that results in the rapid 
consumption of platelets14. However, thrombocytopenia can occur in the absence of 
activation of the coagulation cascade15.  
Infective endocarditis can be difficult to treat with antibiotics even if susceptible 
organisms are involved. This is due poor penetration of the thrombus by some antibiotics 
16
. Also bacteria in a thrombus are isolated from the immune system as thrombi are 
devoid of neutrophils. Platelets are an important part of the host defence because of their 
ability to secrete potent antimicrobial peptides (see below)17.  
The importance of bacterial-platelet interactions in disease pathogenesis is not yet 
fully understood. In recent years important investigations have been carried out into the 
mechanisms employed by different bacterial species for adherence to platelets and for 
their activation. These studies are providing insights into bacterial pathogenesis and 
allowing identification of targets for the development of novel therapeutics against 
vascular infection. In this review we will describe the interactions that occur between 
bacteria and platelets, the bacterial proteins involved, their platelet receptors and the 
mediators of these interactions. We will also discuss how bacteria use these interactions 
to facilitate survival in the harsh environment of the vascular system and how these 
interactions may be targets for therapy or prophylaxis. 
 
Bacterial infections of the cardiovascular system 
The frequency of bacteraemic infections has increased dramatically in recent years, in 
part due to increased use of interventionary procedures including angioplasty and the 
deployment of stents, catheters, pacemakers and prostheses18, 19. Furthermore, the 
increase in antibiotic resistance has contributed to the increase in bacterial infections 
which are refractory to treatment.20 Bacteraemic infection can lead to serious vascular 
complications, including life-threatening endocarditis1, disseminated intravascular 
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coagulation)2 and thrombocytopenia14. In addition, there is evidence suggesting a role for 
infection in conditions such as atherosclerosis21, 22, myocardial infarction23 and stroke6, 24.  
A wide range of bacteria can cause infective endocarditis (IE; Table 1)25. Despite 
improvements in health care, there has been a progressive change in risk factors for IE 26. 
New at-risk groups include intravenous drug users, elderly people with valve sclerosis, 
patients with intravascular prostheses, those exposed to nosocomial disease, and 
haemodialysis patients. Staphylococcus aureus has now surpassed viridans streptococci 
as the most common cause of IE in the developed world27 and taken together, S. aureus, 
streptococci and enterococci are responsible for more than 80% of cases1, 26. Native valve 
IE is classically associated with congenital heart disease and chronic rheumatic heart 
disease indicating that prior valvular damage predisposes to infection. Prosthetic valve 
endocarditis (PVE) occurring shortly after surgery is often caused by Staphylococcus 
epidermidis or S. aureus, whereas later PVE is often due to streptococci and Gram-
negative bacteria such as Haemophilus spp, and Actinobacillus spp26. HIV-1 positive 
patients sometimes present with IE caused by unusual organisms including Bartonella, 
Salmonella, and Listeria26. Periodontal disease, dental procedures and oral hygiene 
practices may lead to bacteraemia caused by oral commensals and occasionally to serious 
cardiovascular disease such as IE or myocardial infarction28. 
Nosocomial endocarditis is a rapidly growing category with many patients having 
no cardiac predisposing factors. The predominant pathogens are staphylococci and 
enterococci, organisms frequently associated with nosocomial sepsis. Importantly, 
nosocomial endocarditis has a case fatality rate greater that 50%1, 26. 
Infection has also been shown to play a role in coronary artery disease. Patients 
who have received antibiotics in the previous year have a reduced risk of MI29-31 while 
those who have had a bacteraemia have an increased risk of MI4. However, recent studies 
have shown no decrease in incidence of MI with antibiotic use32, 33. While specific 
pathogens, especially Helicobacter pylori and Chlamydia pneumonia have been 
associated with increased risk of MI more recent evidence suggests that pathogen burden 
is more relevant to an increased risk of MI22, 23, 34, 35. In addition, animal studies have 
shown that exposure to Porphyromonas gingivalis is as effective as a high cholesterol 
diet at inducing atherosclerosis36-38. Thus, there is evidence to support a role for infection 
in cardiovascular and cerebrovascular disease and that the burden of infection may be 
more important than exposure to a specific agent. However the role infection plays in the 
pathogenesis of atherosclerosis remains to be elucidated. Platelets play an important role 
in atherosclerosis39-41. Platelet interactions with the atherosclerotic lesion are part of the 
inflammatory process and lead to progression of the lesion. Plaque rupture results in the 
formation of a thrombus leading to an acute coronary syndrome (ACS). If this thrombus 
persists and fully occludes the vessel the result is a myocardial infarction. 
Infection may play a role in a number of different stages of atherosclerosis: i) 
trigger vascular inflammation which eventually leads to atherosclerosis ii) accelerate 
inflammation of an existing lesion by recruiting leucocytes and platelets to the lesion iii) 
destabilise an existing lesion iv) enhance thrombus formation on a ruptured lesion. 
 
Biology and function of platelets 
Platelets are anucleate derivatives of megakaryocytes and are the smallest and most 
numerous  (normal range: 3 x 108 to 4 x 108 per ml) corpuscular component of blood42. 
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The typical shape of resting platelets is discoid and upon activation they undergo a shape 
change to a globular form with pseudopodia. Although they are energetically active, 
platelets lack nuclei and can perform only limited translation from stable megakaryocyte 
mRNA43. Platelets contain granules for storage of important mediators such as ADP, 
serotonin, calcium and proteins such as fibrinogen, vitronectin, and von Willebrand 
factor44. Granules also contain platelet microbicidal peptides and proteins. Platelet 
microbicidal proteins (PMP) and thrombin-inducible PMPs (tPMPs) are present in rabbit 
platelet extracts and thrombin-induced supernatants17. 
Platelets play a crucial role in thrombus formation. Firstly, single platelets bind to 
a site of damaged endothelium where the underlying extracellular matrix has been 
exposed. This involves platelet surface receptors for collagen (α2β1 and GPVI), 
fibrinogen (GPIIb/IIIa) and von Willebrand factor (GPIb/IX/V) and results in capture of 
platelets and their activation45. Upon platelet activation, the fibrinogen receptor 
GPIIb/IIIa undergoes a conformational change which allows it to bind soluble 
fibrinogen46. At the same time, cytoplasmic granule contents are released triggering 
activation of other platelets which are then recruited into the growing thrombus plugging 
the endothelial damage. Figure 3 shows the intracellular pathways that occur during 
platelet activation. 
The ability to activate platelets has been exploited by some endovascular 
pathogens to promote colonization and avoidance of the host immune responses.  On the 
other hand, platelets exert anti-bacterial effects through release of microbicidal tPMPs 
upon activation47 which act against a broad spectrum of pathogens including some strains 
of S. aureus, viridans group streptococci and Candida albicans17, 48, 49.  
tPMPs released from platelets include the classical chemokines (kinocidins) 
platelet factor 4, CTAP-3, RANTES, fibrinopeptide B and thymosin β-450-52. Strains of S. 
aureus  that are susceptible to tPMPs in vitro are less likely to cause endovascular 
infections in humans and are more rapidly cleared from the bloodstream than bacteria 
that are resistant53-55. In experimental endocarditis S. aureus cells that are resistant to 
tPMPs in vitro are more virulent56. Resistance to tPMPs in S. aureus  is due to a 
combination of several factors including (i) enhanced membrane fluidity57 (ii) reduced 
membrane potential58, 59 (iii) a high proportion of positively charged groups in the cell 
membrane and the cell wall due to lysinylation of phosphatidyl glycerol and D-
alanylation of teichoic acid60 and (iv) a plasmid-encoded efflux pump61.  
Evidence exists that platelets are capable of engulfing S. aureus cells after 
activation has occurred62, 63 possibly avoiding immune defences63. It is likely that S. 
aureus can survive within platelets as the bacterium possesses many mechanisms for 
avoidance of innate immune responses64, 65. Clearly, the interaction of bacteria with 
human platelets may have different outcomes and this may depend on the strain of 
bacteria which is causing the infection. 
 
Platelet-bacteria interactions 
The association of coagulation with infection has been well established in nature. The 
best characterised example is that of the amebocytes of Limulus polyphemus (horseshoe 
crab). These are the only circulating cell in the crab’s blood and, while nucleate, are very 
similar in morphology to mammalian platelets. Upon exposure to bacteria they aggregate 
and release their granule contents. Thus, the Limulus amebocytes mediate host defense 
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and haemostasis. In mammals the platelet has retained the function of the amebocyte 
despite the development of dedicated immune cells66. 
Early studies on the interaction of bacteria with platelets focused on the effects of 
endotoxin on platelet activation67. A study in 1959 showed platelets interacting with 
mycobacteria68 and a series of studies by Clawson and co-workers during the 1970’s 
examined the response of platelets to whole bacteria69-74. However the development of a 
method to measure platelet aggregation10 and the availability of commercial platelet 
aggregometers was to lead to further studies of platelet interactions with bacteria.  
Platelets have also been shown to respond to exposure to antigen-antibody complex75 as 
well as to complement76 and to secrete bactericidal agents77 in response to activation, 
suggesting a role for platelets in the immune response to infection. However, these 
studies were limited by a paucity of information on platelet function and they provided 
little information on the platelet proteins involved in the interaction and how the 
interaction resulted in platelet aggregation. Below we describe some of the most 
important and best characterised bacteria that are known to interact with platelets. 
 
 
The interactions of Staphylococcus aureus with platelets 
   Probably the best characterized interaction between bacterial cells and 
platelets are those involving the major IE pathogen S. aureus. While the initial studies 
focused on secreted mediators of platelet activation such as α-toxin78 Hawiger and co-
workers showed that staphylococci can trigger platelet aggregation involving protein A, 
IgG and the Fc receptor on platelets79. Subsequently, clumping factor was shown to be an 
important mediator of S. aureus adhesion to fibrinogen and to be a virulence factor for 
endocarditis80 and this interaction was suggested to be independent of GPIIb/IIIa, the 
platelet fibrinogen receptor81. In fact S. aureus has several different surface-associated 
proteins that are capable of binding to platelets and in some cases of stimulating platelet 
activation (Table). The proteins typically have signal sequences at their N-termini which 
direct Sec-dependent secretion through the cytoplasmic membrane and at their C-termini 
a sorting signal for anchoring the protein to the cell wall 82. Clumping factor A comprises 
a ~500 residue fibrinogen binding domain which is projected from the cell surface by an 
unfolded serine and aspartate dipeptide repeat region (Figure 2). It is the prototype of a 
family of related proteins with structurally similar N-terminal ligand-binding domains. 
The fibronectin-binding proteins FnBPA and FnBPB have an N-terminal A domain that 
has sequence similarity to ClfA and which interacts with the same region of fibrinogen as 
ClfA.  The A domains of the FnBPs are linked to the cell surface by a series of tandemly-
repeated unfolded fibronectin-binding determinants83, 84. In the case of FnBPA, two 
molecules of fibronectin can interact with each fibronectin binding region83.   
Early studies showed that S. aureus could adhere to platelets in a manner that was 
enhanced by the presence of fibrinogen85. A mutant of S. aureus that lacked the ability to 
bind platelets had a transposon insertion in the clfA gene implying that a fibrinogen 
bridge occurred between ClfA on the bacterial surface and a platelet fibrinogen binding 
protein, probably the integrin GPIIb/IIIa 86. It was also suggested that ClfA could bind 
directly to an as yet unidentified protein of 118 kDa on the platelet surface87. By studying 
strains with one or more mutations affecting surface proteins and by expressing surface 
proteins separately in a heterologous host (eg. Lactococcus lactis), clumping factors ClfA 
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and ClfB, fibronectin binding protein A and the serine aspartate repeat protein SdrE were 
all shown individually to be able to bind platelets and to stimulate platelet aggregation8.  
More recently our groups have analyzed in detail the molecular basis of platelet 
activation by extending this approach to different host strains and by studying cells in 
different phases of growth. Firstly, the major determinants of the ability of S. aureus to 
promote rapid activation of platelets differ according to the phase of growth of the 
culture. With cells from stationary phase, ClfA is the dominant pro-aggregatory surface 
protein88 whilst with cells from exponential growth the fibronectin-binding proteins are 
of major importance89. This correlates with regulation of expression of the genes that 
encode the proteins. The fnbA and fnbB genes are only transcribed in exponential phase 
of growth90 whilst clfA is transcribed weakly in exponential phase and is stimulated in a 
SigB-dependent fashion in stationary phase91. By using a regulatable promoter to control 
expression of surface proteins in the surrogate host Lactococcus lactis it was shown that a 
minimum number of ClfA and FnBPA protein molecules were required on the bacterial 
surface before activation of platelets could occur88.  Once the threshold was achieved 
aggregation occurred rapidly.   
By studying a mutant of ClfA that did not bind fibrinogen, by using inhibitors  
specific for platelet receptors and by analysing the soluble plasma proteins required in a 
reconstituted plasma-free system with washed platelets it was possible to identify the 
plasma and platelet components involved88. For rapid activation to occur the bacteria 
must express sufficient ClfA molecules on their surface and bind fibrinogen molecules in 
plasma. GPIIb/IIIa on resting platelets has a low affinity for fibrinogen but can still bind 
bacterial-bound fibrinogen. However this is not sufficient to stimulate activation. ClfA-
specific immunoglobulin must also be present to acts a bridge between the bacterial 
surface protein and the platelet immunoglobulin Fc receptor, FcγRIIa88 (Figure2a).  
Similar observations were made with the fibronectin binding protein FnBPA 
which possesses two different but related mechanisms of engaging and activating resting 
platelets89. The fibrinogen-binding A domain behaves in a similar fashion to ClfA and 
activates platelets via a fibrinogen bridge to GPIIb/IIIa and an IgG bridge to FcγRIIa. In 
addition, the fibronectin-binding region BCD can independently activate platelets. This 
requires fibronectin N-terminal type I domains to bind to the bacterial protein by the 
tandem β-zipper mechanism83and to GPIIb/IIIa via the integrin-binding RGD domain89. 
As with ClfA and the FnBPA A domain, specific antibody (in this case recognizing the 
neo-epitopes created when FnBPs bind fibronectin92) is also required in order to engage 
FcγRIIa89  (Figure 2b). FnBPB appears not to be as effective at inducing platelet 
aggregation93 although our results contradict this89.  
Soluble fibrin, which is derived from fibrinogen by the actions of thrombin, is 
more potent than fibrinogen in promoting platelet activation and aggregation by S. 
aureus
85, 94
. This suggests that S. aureus may have a high affinity for an existing lesion 
containing a fibrin clot and may play a role in colonising a damaged valve. If fibrin is 
generated thrombin must be present, which as a potent platelet activator would lead to 
thrombus formation. However, it does not explain how S. aureus can colonize 
undamaged valves to cause native valve endocarditis. In fact, S. aureus is capable of 
directly activating platelets independently of thrombin generation. This is supported by 
our observation that the presence of a thrombin inhibitor only marginally decreased the 
potency of S. aureus-promoted aggregation89.   
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In conclusion, rapid platelet activation mediated by ClfA and FnBPs requires two 
mechanisms of binding bacteria to resting platelets (i) a fibrinogen or fibronectin bridge 
to the low activity platelet integrin and (ii) an immunoglobulin bridge to the FcγRIIa 
receptor. It is likely that clustering of FcγRIIa initiates the signal transduction cascade 
that causes the subsequent activation and aggregation of platelets (Figure 3). Activation 
thus depends on the presence of specific antibodies which are present in the sera of most, 
if not all individuals95.  
Although, ClfA and FnbpA/FnbpB appear to be the dominant surface proteins 
mediating platelet aggregation in stationary and exponential phase respectively, 
additional factors including ClfB, SdrE and SpA have also been shown to play a role8. 
SpA had previously been reported to bind platelets through the gC1qR/p33, a platelet 
complement receptor96. However, gC1qR/p33 is an intracellular protein on resting 
platelets and is only exposed when platelet are activated. SpA binds with high affinity to 
the A1 domain of von Willebrand factor (vWF), a large multimeric glycoprotein which 
mediates platelet adhesion at sites of endothelial damage97, 98. Recent evidence suggests 
that SpA plays an important role in mediating interactions with platelets under conditions 
of high shear62 (see section, Bacteria-platelet interactions under high shear conditions). 
Recently a high molecular mass protein called SraP which is homologous to the 
GPIb binding protein GspB of Streptococcus gordonii (see below) was shown to promote 
binding of S. aureus cells to platelets and to enhance virulence in a rabbit model of 
endocarditis99 SraP did not appear to bind to GPIb and it was not clear if its interaction 
with platelets stimulated activation.    
S. aureus can also activate platelets by a slower mechanism that is independent of 
GPIIb/IIIa. A non-fibrinogen-binding mutant of ClfA (ClfA-PY) caused slow activation 
of platelets88, as did SdrE, a surface protein which was previously shown to activate 
platelets when expressed in L. lactis8,  but which does not bind fibrinogen. ClfA-PY and 
SdrE-expressing bacteria stimulated activation of platelets after a lag phase lasting 
between 8 and 20 minutes depending on the plasma donor and the level of protein 
expression on the bacteria cell surface.  In both cases IgG specific for the surface protein 
was required to engage FcγRIIa and also to provide the stimulus for activation of 
complement by the classical pathway. Assembled complement components on the 
bacterial cell surface then bound to complement receptors on the platelet surface. Both 
complement and antibody are required for activation to occur (Figure 2c).  Some strains 
of Streptococcus sanguis can also activate platelets in a complement-dependent fashion100 
(see below). Indeed this mechanism might be widespread among bacterial IE pathogens 
that do not express potent activating molecules like ClfA or FnBPA.  To put it in more 
general terms, any bacterium should be capable of activating platelets (i) when it 
expresses a surface protein or proteins at a sufficiently high level and (ii) provided there 
are antibodies to the proteins present. The latter condition is likely to be met because 
most IE pathogens are commensals and most individuals have been exposed and have 
antibodies to the bacterial surface proteins in their sera95. 
 
Interaction of streptococci with platelets 
The viridans group of streptococci are usually commensals of the human oral 
cavity and may contribute to tooth decay. Very occasionally they gain access to the 
vascular system and cause infective endocarditis. Until recently S. sanguis was the most 
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common cause of IE but has now been superceded by S. aureus27. Studies using animal 
models of endocarditis have shown that the ability of S. sanguis to adhere to and activate 
platelets correlates with increased severity of disease101. 
Initial studies identified M-protein isolated from Group A streptococci as 
mediating platelet aggregation in an antibody and complement-dependent manner102. 
Subsequently S. pyogenes103 and S. sanguis were shown to directly trigger platelet 
aggregation104. 
A collagen-like component of S. sanguis was implicated in platelet aggregation105. 
This was subsequently identified as platelet-aggregation-associated protein (PAAP)105, 
106
. PAAP is a rhamnose-rich glycoprotein of 115 kDa which contains a collagen-like 
platelet-interactive domain comprising residues Pro-Gly-Glu-Gln-Gly-Pro-Lys106. Gong 
and colleagues reported that PAAP interacts with platelet membrane proteins of 175 kD 
and 230 kD to mediate platelet binding and aggregation107. However, it has recently been 
shown that the role of PAAP in platelet aggregation is donor-specific108.  
S. sanguis was found to require IgG interacting with the platelet FcγRIIa receptor 
to mediate platelet aggregation109. However, there is no clear association between IgG 
levels, FcγRIIa polymorphisms and donor variability110. A role for complement and IgG 
was also proposed100, 111 and anti-GPIb antibodies were found to be inhibitory7, 112. 
A major problem with these studies is that there is considerable variation in the 
ability of different S. sanguis strains to stimulate platelet aggregation. Kerrigan et al. 
identified three different phenotypes for platelet interactions7. Type I strains showed 
strong adhesion and rapid aggregation of platelets. Type II strains had longer lag times to 
platelet activation and did not support bacterial adhesion to resting platelets while type III 
strains did not adhere to or activate platelets7. Presumably there is potential for a type IV 
strain that supports platelet adhesion but does not induce aggregation. In fact the data 
suggests that the ability to support platelet adhesion is distinct from the ability to induce 
platelet aggregation and both adhesion and aggregation are likely to be mediated by 
different bacterial proteins as well as by different platelet receptors.  
Platelet activation by type I strains is mediated by a direct interaction between the 
bacterial cell and GPIb, the platelet vWF receptor (Figure 4b). The interaction with GPIb 
was localised to the N terminal 1-225 residues of GP1bα7. The S. sanguis protein that 
interacts with GPIb is the glycoprotein serine-rich protein A (SrpA), a homologue of 
Streptococcus gordonii Hsa and GspB proteins113. However, deletion of this protein does 
not abolish aggregation but it does prolong the lag-time113, in effect converting a type I 
strain into a type III strain. For type III strains with a long lag time, activation required 
specific antibody and complement assembly similar to slow activation promoted by S. 
aureus discussed above109, 111, 114. The signalling pathway stimulated by a  S .sanguis 
strain that induced slow (~12 min) aggregation was shown to be that illustrated in Figure 
3A115. After rapid phosphorylation of FcγRIIa to initiate the pathway, the proteins 
became dephosphorylated (Figure 3b) prior to aggregation and were re-phosphorylated 
once aggregation occurred.  
Despite inhibition of fast S. sanguis-induced platelet aggregation by antibodies to 
FcγRIIa there was no evidence for a direct role for IgG since aggregation occurred in an 
antibody-free system with only fibrinogen present7. However, it must be noted that 
commercial fibrinogen is contaminated with IgG88 and there may have been sufficient 
present to support an antibody-mediated response. Alternatively, since FcγRIIa and GPIb 
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co-localize it is possible that the anti-FcγRIIa antibody might sterically block GPIb116.  
Another member of the viridans group of streptococci that causes IE is S. 
gordonii117. An early report suggested that S. gordonii strains could not stimulate platelet 
aggregation118. However, subsequent studies showed that S. gordonii can bind to platelet 
GPIb via GspB119, 120 and are capable of stimulating platelet activation121.  It is now well 
established that S. gordonii can adhere to platelets and this interaction may contribute to 
the establishment of endovascular vegetations characteristic of IE121, 122. GspB is a 286 
kDa surface-anchored protein that mediates adherence to platelets by interacting with 
GPIb. GspB is translocated from the cytoplasm to the cell wall by a dedicated transport 
system comprising, at least in part, of the  SecA2 and SecY2 proteins121, 122. Several 
genes encoding glycosyl transferases lie adjacent to the gspB, secA2 and secY2 genes 
suggesting that they are involved in glycosylation of GspB119, 123, 124. A homologue of 
GspB known as Hsa, made by a different strain of S. gordonii is nearly identical to GspB 
at its N terminus suggesting it may have a related function120 and may have the ability to 
bind to GPIIb/IIIa as well125. Hsa is a 203 kDa sialic acid-binding glycoprotein that 
mediates binding to platelets and platelet aggregation121. Both GspB and Hsa mediate 
binding to sialic acid residues on the platelet receptor GPIb, suggesting that GPIb is a 
major receptor for S. gordonii-platelet interactions120. Hsa binds specifically to the N-
linked oligosaccharides on the globular N-terminal domain of GPIbα while GspB binds 
to oligosaccharides in this region as well as in the membrane proximal mucin core126. The 
primary function of Has/GspB is to support bacterial adhesion to salivary proteins127, 128 
and the ability to interact with GPIb appears to be a novel function. Mutation of Hsa been 
shown to reduce endocarditis in an animal model129. 
S. mitis has been shown to bind to platelets130 and mediates adherence through 
surface proteins PblA and B but does not appear to directly activate platelets118. S. 
pyogenes has also been shown to induce platelet aggregation103 and to contain a collagen-
like protein131 while S. pneumoniae induces aggregation in an antibody-dependent 
manner
132
. 
S. agalactiae is an important human pathogen that causes pneumonia, sepsis and 
meningitis in neonates. It also poses a serious threat to immuno-compromised adult 
patients causing arthritis, urinary tract infections and endocarditis. In a similar manner to 
S. aureus ClfA, a fibrinogen-binding protein made by S. agalactiae (FbsA) mediates 
attachment to and aggregation of platelets in a fibrinogen- and specific IgG-dependent 
manner133. 
   
 
Bacteria-platelet interactions under high shear conditions 
Most of the experiments analysing bacteria-platelet interactions have been carried out 
under static or low shear conditions. However the vascular system, especially arterioles, 
presents conditions of high shear. It is important that the molecular mechanisms of 
activation are tested under high shear to simulate better in vivo conditions. It is likely that 
hydrodynamic shear will affect the molecular interactions between platelets and S. aureus 
in the vascular system. Pawar and colleagues demonstrated a key role for SpA in 
mediating platelet activation at high shear rates62. It should be noted that SpA binds to 
vWF with a Kd in the low nM range97. We have recently shown that each of the five SpA 
domains (A-E) can individually bind to the A1 domain of vWF with similar high 
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affinity98. A monoclonal antibody directed against vWF partially inhibited platelet 
activation under these conditions and an antibody specific for the platelet receptor for 
vWF (GPIb) also partially inhibited Spa-mediated activation suggesting that an SpA-
vWF cross-bridge links SpA on the bacterial surface with the platelet vWF receptor GPIb 
(Figure 4b). It is possible that plasma IgG molecules bound to SpA compete with vWF by 
occluding the vWF binding site on SpA62.  However the affinity of the vWF-SpA 
interaction is sufficiently high to withstand this. The fibrinogen-binding protein, ClfA, 
was able to mediate platelet adhesion through the GPIIb/IIIa receptor under both low and 
high shear rates. Hydrodynamic shear affected the receptor specificity of activation-
dependent platelet binding to S. aureus cells, as evidenced by the transition from a SpA-
independent/ClfA-dependent process at low shear to a SpA-dependent process at high 
shear62.  
 When passed over immobilised S. sanguis under high shear conditions, platelets 
first rolled and then adhered, subsequently forming a large thrombus. This is 
characteristic of the interaction of platelets with von Willebrand factor bound to exposed 
collagen at damaged endothelial surfaces, a mechanism that occurs during blood clot 
formation. Although the rolling mediated by vWF only occurred under high shear 
conditions, platelet rolling over immobilised S. sanguis could also occur under low shear 
conditions. This interaction was shown to be mediated by GPIb on the platelet and by 
SrpA on the bacteria113.  
Thrombus formation by Streptococcus pyogenes has also been studied under 
conditions of high shear134. S. pyogenes M protein promoted thrombus formation with 
fibrinogen- and M protein-specific IgG being essential, indicating that S. pyogenes and S. 
aureus share common mechanisms of rapid platelet activation134. 
 
Interaction of Porphyromonas gingivalis with platelets 
The oral pathogen P. gingivalis has been shown to accelerate atherosclerosis36-38 
and to secrete a platelet activating protease135. P. gingivalis has been show to directly 
activate platelets136. This depends on expression of a surface adhesin Hgp44 which is 
processed from haemagglutinin A by surface associated cysteine proteases. Activation 
requires antibody in serum to bind to antigens on the bacterial cell surface to interact with 
FcγRIIa on platelets. A role for GPIbα was indicated by monoclonal antibodies 
recognizing various domains of GPIbα causing partial or complete inhibition of 
aggregation and by proteolytic cleavage of the N –terminal domain inhibiting activation.  
However it is not clear if Hgp44 binds directly to GPIbα or if the platelet glycoprotein’s 
involvement is due to its close proximity to FcγRIIa. 
 
Interaction of Helicobacter pylori with platelets 
Helicobacter pylori causes gastritis, peptic ulcers and gastric carcinoma, mucosa-
associated lymphoid tissue (MALT) lymphoma and pernicious anaemia137. Recent 
evidence also suggests that H. pylori may have pathogenic effects outside of the 
gastrointestinal tract. Infection with H. pylori seems to increase the risks of 
atherosclerosis138, 139 immune thrombocytopenic purpura (ITP)3, 11, 12. ITP is caused by 
destruction of platelets, probably by auto-antibodies. H. pylori infections have been 
identified in patients with ITP and platelet counts increased after elimination of 
infection3. Furthermore some H. pylori strains could induce platelet activation and 
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aggregation which appears to be mediated through initial interaction of von Willebrand 
factor (vWF) with bacteria in the blood followed by binding to GPIb, the platelet vWF 
receptor. Function-blocking antibodies specific for either vWF or GPIb disrupted H. 
pylori-mediated platelet aggregation140. Specific anti-H. pylori antibodies were also 
required as was an interaction with FcγRIIa. The requirement for vWF in H. pylori-
induced aggregation suggests a different mechanism compared to S. sanguis which also 
requires GPIb but not vWF7, although binding of bacterial-specific IgG to the platelet 
FcγRIIa receptor is common to both bacteria. 
Campylobacter fetus infection has been associated with thrombosis in a number 
of case reports141 although there is no information on a potential interaction with platelets 
although C. rectus has been shown not to induce platelet activation142. 
 
Borrelia-platelet interactions 
Borrelia burgdorferi is a tick-borne spirochaete that is the causative agent of Lyme 
disease, a chronic, multisystemic infection affecting humans in specific geographical 
regions in the USA and Europe. After several days of localised skin infections at the site 
of the tick bit, the spirochete disseminates to multiple tissues including the synovium, the 
central nervous system and the heart143. B. burgdorferi binds to activated platelets via the 
GPIIb/IIIa platelet receptor144. This interaction may occur through a B. burgdorferi 
surface protein p66145. However, it is not clear whether binding occurs directly or through 
a plasma protein.  A prominent feature of Lyme disease is vascular injury. This may 
result in localised platelet activation and aggregation, which may then lead to B. 
burgdorferi adherence to platelets. This interaction may contribute to colonisation and/or 
dissemination to other regions of the vascular system. 
 Borrelia hermsii is a tick-borne spirochaete, which is the causative agent of 
relapsing fever. B. hermsii grows to high density in blood and platelet-spirochete 
complexes have been observed in blood smears of relapsing fever patients146. Similarly to 
B. burgdorferi, B. hermsii was shown to bind to platelets through the GPIIb/IIIa receptor 
of both activated and resting platelets147. In contrast, B. hermsii induced platelet 
activation in the absence of added fibrinogen 147. B. hermsii infection of mice resulted in 
severe thrombocytopenia and spirochete complexes were detected in the blood of 
infected mice, however, there was no evidence of platelet activation and binding of the 
spirochaete to the platelets was independent of GPIIb/IIIa148. This suggests that the 
platelet-bacterial complexes are cleared from the circulation and that the activation 
process in mice platelets may differ from that of human platelets. 
 
A general mechanism for platelet activation mediated by surface proteins of 
vascular pathogens.  
Increasing evidence indicates that many bacterial pathogens employ a similar basic 
mechanism for mediating platelet activation. Initial adhesion of bacteria to platelets 
occurs either through direct adherence or more commonly through a plasma protein 
bridge with a platelet receptor, usually GPIIb/IIIa or GPIb. This interaction in itself is 
insufficient for platelet activation but requires circulating antibody specific for the 
bacterial surface protein to engage the platelet FcγRIIa receptor. This leads to platelet 
activation and results in platelet aggregation and thrombus formation. Many of the 
pathogens that cause IE are normal human commensals to which the host has been 
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exposed so that low levels of specific antibodies are present in blood95. Bacteria seem to 
utilise these antibodies to subvert the immune response to promote pathogenesis. High 
levels of antibodies will actually prevent activation by blocking the ligand-binding 
activity of the surface protein. In this case a slower complement-dependent mechanism of 
platelet activation can be employed by the pathogen. With  Helicobacter pylori140 only 
the sera of individuals who have been infected have antibodies that would be capable of 
promoting activation. 
 
Bacterial extracellular factors which mediate platelet interactions 
The  α-toxin of S. aureus can potently induce aggregation of platelets and contribute to 
coagulation of blood9, even at concentrations below those which cause cytolysis. α-toxin 
initiates prothrombinase complex formation on platelets149. The process resembles that of 
ionophore agonists by creating ion channels that simulate Ca2+ flux (Figure 3C). 
Paradoxically, elevated expression of α-toxin by S. aureus leads to reduced virulence in a 
rabbit model or endocarditis150. This was likely to be due to excessive damage to platelets 
causing release of PMPs rather than reduced clearance during the bacteraemic phase or to 
reduced adherence of bacteria to thrombi.   
S. aureus can produce at least one protein which blocks activation of platelets. 
The extracellular fibrinogen binding (Efb) protein is made during post-exponential 
growth. It binds fibrinogen and can also bind directly to a receptor on activated 
platelets151, 152. It enhances fibrinogen binding to platelets independently of GPIIb/IIIa 
(Figure 5) but blocks platelet aggregation, presumably by altering the conformation of 
GPIIb/IIIa-bound fibrinogen so it cannot crosslink with another platelet (Figure 5). An S. 
aureus efb mutant showed decreased virulence in a model of staphylococcal wound 
infection and the presence of Efb contributed to a delay in wound healing151, 152. 
Enterotoxin B secreted from S. aureus has also been shown to inhibit thrombin-induced 
platelet aggregation153. This suggests that activation of platelets by S. aureus may be 
disadvantageous in certain disease situations and that S. aureus has evolved mechanisms, 
via Efb and enterotoxin B, to avoid this outcome. The S. aureus efb mutant was not 
attenuated in an endocarditis model152.  
Bacillus anthracis express two toxins that potently inhibit aggregation of platelets 
by natural agonists. The edema toxin (ET) is a calmodulin-dependent adenylate cyclase 
that activates cAMP dependent protein kinase A inside cells and platelets, an event which 
is likely to initiate events leading to failure to aggregate154. The lethal toxin has a 
completely different mode of action by suppressing p42/44 and p38 mitogen-activated 
protein kinase pathways155. The action of these two toxins suggests that the platelet is an 
important target in the pathogenesis of anthrax and helps explain the haemorrhages which 
are a feature of the infection.  Haemorrhages also occur during whooping cough caused 
by Bordetella pertussis adenylate cyclase toxin which is attributed to inhibition of platelet 
function probably by a similar mechanism to B. anthracis ET156. 
Periodontitis is a chronic infectious disease in which proteolytic activity 
contributes to the destruction of tooth-supporting tissue28, 157. Several studies have linked 
periodontal disease to heart disease28, 157-159. Porphyromonas gingivalis is one of the 
major causes of adult periodontitis160. Gingipains, a family of cysteine proteases 
produced by P. gingivalis contribute to the pathogenesis of periodontitis161, 162. 
Gingipains can directly activate platelets resulting in platelet aggregation which required 
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the proteolytic activity of the gingipains and involved stimulation of protease-activated 
receptors (PAR-1 and PAR-4) on the platelet surface163. This mechanism is distinct from 
activation promoted by surface adhesins on P. gingivalis cells136 described above. 
Pseudomonas aeruginosa occasionally causes infective endocarditis, particularly in 
intravenous drug abusers26. P. aeruginosa produces a phospholipase C (PLC) enzyme 
which stimulates platelet aggregation in a manner which is dependent on the enzymatic 
activity PLC164. Water soluble extracts of H. pylori have been shown to induce platelet 
aggregation165. S. mitis has been shown to secrete a platelet activating factor166 while S. 
mutans-induced platelet aggregation is mediated by a soluble polysaccharide in an 
antibody-dependent manner167. 
 
Outlook for novel therapeutics and avenues for future research.  
The discovery of a common mechanism of platelet activation by several important 
pathogens provides increased hope for the development of novel therapeutics for treating 
serious vascular infections such as IE. In particular, the identification of the crucial role 
of the FcγRIIa receptor in bacteria-induced platelet activation represents an interesting 
target for further investigation. Additional analysis will determine if this is a truly 
universal mechanism. The identification of several host factors that are important for 
bacterium-platelet interactions suggests that some individuals might be more susceptible 
to or conversely, more resistant to serious complications of bacteraemia. In addition, 
several bacterial factors that promote interaction with platelets and contribute to 
pathogenesis have now been identified. Development of specific monoclonal antibody 
therapies against these proteins may prove to be useful in treating or preventing serious 
cardiovascular infections. Ideally small molecule inhibitors of the interaction between 
platelets and bacteria could be developed which would have the advantage of by-passing 
antibiotic resistance mechanisms. Accordingly, they would be ideal for prophylaxis of 
infection in susceptible individuals and would allow restriction of antibiotic therapy to 
cases of overt infection. 
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Table. 1 Bacterial agents of vascular infections and reported interactions with platelets  
Bacterial 
pathogen 
Vascular disease 
association 
Platelet 
adherence/ 
aggregation 
Bacterial factors Host 
factors 
Staphylococcus 
aureus 
IE +164 ClfA8, 88 
 
 
 
 
ClfB8 
 
FnbA, FnbB89 
 
 
 
 
 
 
SpA8, 62 
SdrE8 
 
SraP99Efb152 
α-toxin9 
Fibrinogen 
GpIIbIIIa 
FcγRIIa 
IgG88, 89 
 
“   “ 
 
Fibrinogen 
fibronectin 
GpIIbIIIa 
FcγRIIa 
IgG88, 89 
 
 
vWF 
complement 
IgG 
Not known 
Not known88, 89 
Staphylococcus 
epidermidis 
IE +168 
 
 
SdrG 
 
(unpublished data) 
Fibrinogen 
GPIIb/IIIa 
FcγRIIA 
IgG 
Staphylococcus 
capitis 
IE +168 ? ? 
Streptococcus 
sanguis 
IE +118 SrpA 
PAAP113 
GP1b 
FcγRIIa 
113
 
Streptococcus 
agalactiae 
IE +133 FbsA133 Fibrinogen 
IgG133 
Streptococcus 
pyogenes 
IE +103 M protein FcγRIIa 
Streptococcus 
gordonii 
IE +122 GspB119, 120 
HsA121 
GP1b119, 120 
Streptococcus 
pneumoniae 
IE +169 ? ? 
Streptococcus 
mitis 
IE +130 PblA and B, 
Sm-hPAF 
? 
Enterococcus 
spp 
IE +170 ? ? 
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Neisseria 
gonnorrhoeae 
 
IE 
 
? 
 
? 
 
? 
Pseudomonas 
aeruginosa 
IE +164 PLC 164 ? 
Porphyromonas 
gingivalis 
IE 
 
+163 
 
Gingipains171 
Hgp44  
FcγRIIa171 
GPIbα? 
Helicobacter 
pylori 
Myocardial 
infarction 
+140 ? vWF 
GP1b 
IgG140 
Borrelia 
burgdorferi 
Lyme disease +144 p66145 GPIIb/IIIa144 
Borrelia hermsii thrombocytopenia +147 ? GPIIb/IIIa147 
Haemophilus 
influenzae 
Myocardial 
infarction 
? ? ? 
Actinobacillus IE +172 ? ? 
Candida spp. IE +173 ? ? 
Chlamydia 
pneumoniae 
atherosclerosis +174 ? ? 
Listeria 
monocytogenes 
IE +175 ? ? 
Staphylococcus 
aureus 
Delayed wound 
healing 
Inhibition Efb ? 
Bacillus 
anthracis 
Haemorrhage  Inhibition Oedema toxin 
 
Lethal factor 
Protein kinase 
A 
 
MAP kinase 
pathway 
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Figure  1. Platelet activation and aggregation. 
Sequence of events that occur when bacterial cells bind to platelets and stimulate 
activation. A and B: Bacteria bind to a platelet receptor, either directly or via (a) bridging 
ligand(s). C.  Signal transduction cascade is stimulated. This leads to activation of the 
platelet integrin GPIIb/IIIa and expression of more molecules on the platelet surface. D. 
The activated GPIIb/IIIa binds to soluble fibrinogen in plasma which causes aggregation. 
 
Figure 2.  Mechanism of bacteria-mediated platelet adherence and activation. 
Diagrams summarizing platelet activation involving the immunoglobulin receptor  
FcγRIIa. A. Rapid activation involving a fibrinogen bridge between a bacterial binding 
protein (ClfA, FnBP) and low affinity resting GPIIb/IIIa and specific IgG which engages 
FcγRIIa.   B. Rapid activation involving a fibronectin bridge between FnBP and the 
platelet integrin GPIIb/IIIa and IgG specific for neo-epitopes created when FnBP binds 
fibronectin which engages FcγRIIa. C. Slow activation involving antibody recognizing a 
surface protein which stimulates complement fixation.  Activation involves IgG engaging 
FcgRIIa and complement being recognized by a platelet complement receptor 
 
Figure 3.  Signalling Pathways in Platelet Activation176-178  
A: Platelets contain a low affinity receptor for the Fc portion of IgG called FcγRIIa. 
Upon binding the Fc region of antibody the receptor dimerizes. This requires antibody to 
be bound to a surface or to be agglutinated. Not only can Fc form homodimers but it can 
also form heterodimers with GPIb, the von Willebrand factor receptor or complement 
receptors. After dimerization tyrosine residues in the ITAM (immunoreceptor tyrosine-
based activation motif) domain are phosphorylated by a Src kinase, probably Lyn. The 
tyrosine kinase Syk then binds to the phosphotyrosine residues and  phosphorylates 
tyrosine residues in the adapter protein LAT. This results in the recruitment and 
activation of PLCγ2. PLCγ2 produces inositol triphosphate (IP3) which binds to a calcium 
ion channel allowing an influx of calcium from internal stores.  Also produced is 
diacylglycerol (DAG) which activates protein kinase C (PKC) which triggers 
downstream events ion activation. Phosphoinositide-3 (PI3) kinase binds to dimerized 
receptor and plays an important role in actin assembly which is essential for platelet 
aggregation.  
B. The signal is terminated by the action of a number of phosphatases:  PTP1B acts to 
dephosphorylate LAT,  SHP-1 is recruited to the phosphorylated receptor and acts to 
dephosphorylate Syk while SHIP-1 is an inositol phosphatase and acts to inhibit PI3 
kinase activity.  
C: Platelets can be activated by many different agents including ADP, thrombin, 
collagen, and adrenaline. Activation of receptors by these agonists initiates two distinct 
signalling pathways. The first is the mobilization of phospholipase A2 which cleaves 
arachidonic acid (AA) from the membrane of the platelet. This arachidonic acid is then 
converted to prostaglandin H2 (PGH2) by cyclooxygenase (COX). PGH2 is then 
converted to thromboxane A2 (TxA2) by thromboxane synthase (TXS). TxA2 is secreted 
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by the platelet and can activate other platelets as well as being a potent vasoconstrictor. A 
second pathway of platelet activation involves the activation of phospholipase C (PLC) 
which releases inositol triphosphate (IP3) and diacylglycerol (DAG) from the platelet 
membrane. IP3 binds to its receptor on the endoplasmic reticulum triggering the release of 
Ca2+ from internal stores. DAG acts to activate protein kinase C (PKC). The actions of 
Ca2+ influx and PKC lead to activation of GPIIb/IIIa which can then bind its ligand 
fibrinogen. As a divalent molecule, fibrinogen can bind to two GPIIb/IIIa molecules 
simultaneously. If these are on different platelets the result is the formation of a platelet 
aggregate. Weak agonists only trigger PLA2 activation while strong agonists trigger PLC 
activation. In many cases PLA2 is involved with low doses of agonist and PLC becomes 
involved at higher doses. Aside from causing the formation of a thrombus, platelet 
activation causes a number of other responses. Intracellular granules fuse with the 
membrane and release their contents. These include many vasoactive substances and 
growth factors as well as microbicidal peptides. Activated platelets also undergo the 
membrane “flip-flop” where intracellular phospholipids are translocated to the surface. 
These phospholipids allow the assembly of complexes of coagulation factors including 
the FXase complex and prothrombinase complex. Thus, activated platelets play an 
important trigger of the coagulation system. Bacteria that cause activation and 
aggregation stimulate these pathways by interaction with FcγRIIa or GPIbα. 
  
Figure 4. Bacterial interactions involving platelet glycoprotein GPIb 
Binding to GPIb on platelets. A. A model for the interaction of S.aureus with platelets 
involving a von Willebrand factor bridge between protein A  and GPIb. B. Direct binding 
to GPIb mediated by streptococcal surface proteins    
 
 Figure 5.  Platelet interactions of the staphylococcal secreted proteins, Efb and α-toxin. 
The secreted protein Efb can bind to GPIIb/IIIa and fibrinogen resulting in both enhanced 
binding to fibrinogen (A) and inhibition of platelet aggregation (B). α-toxin stimulates 
platelet activation through prothrombinase complex formation leading to ion channels 
which stimulate Ca2+ flux (C). 
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